ITGA4/CD49d (Natalizumab biosimilar) Antibody from ABBEXA LTD
Search, find, compare suppliers for anti-ITGA4/CD49d (Natalizumab biosimilar) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | ITGA4/CD49d (Natalizumab biosimilar) |
| Clone | monoclonal |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG4 kappa |
| Format | Protein A/G purified |
| Size | 100 µg, 1 mg, |
| Concentration | typically between 0.5-2.0 mg/ml. |
| Applications | ELISA, WB |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Natalizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ITGA4/CD49d, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Natalizumab is a recombinant, humanized monoclonal antibody, binds to ?4?1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses. |
| Immunogen | n/a |
| Other Names | Natalizumab, ITGA4/CD49d, 189261-10-7 |
| Gene, Accession # | CAS: 189261-10-7 |
| Catalog # | abx831019 |
| Price | please inquire |
| Order / More Info | ITGA4/CD49d (Natalizumab biosimilar) Antibody from ABBEXA LTD |
| Product Specific References | n/a |
ABBEXA LTD
ABBEXA LTD
181 Cambridge Science Park
Cambridge, CB4 0GJ UK
P: +44 (0) 1223 755950
Customer Service: info@abbexa.com
Technical Support: support@abbexa.com
Orders: orders@abbexa.com
https://www.abbexa.com
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950
Profile of ABBEXA LTD
Return to Antibodies